Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Effect of Low-Dose Celecoxib on SMN2 in Patients With Spinal Muscular Atrophy (SMA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02876094
Recruitment Status : Recruiting
First Posted : August 23, 2016
Last Update Posted : July 30, 2019
Families of Spinal Muscular Atrophy
Gwendolyn Strong Foundation
Information provided by (Responsible Party):
Hugh McMillan, Children's Hospital of Eastern Ontario

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : July 2020